ICON plc Earnings Calls

Q1 2025 Beat
$3.19 (3.57%)
Release date Apr 30, 2025
EPS estimate $3.08
EPS actual $3.19
EPS Surprise 3.57%
Revenue estimate 2.041B
Revenue actual 2.001B
Revenue Surprise -1.95%
Q4 2024 Beat
$3.43 (0.587%)
Release date Feb 19, 2025
EPS estimate $3.41
EPS actual $3.43
EPS Surprise 0.587%
Revenue estimate 2.036B
Revenue actual 2.041B
Revenue Surprise 0.245%
Q3 2024 Missed
$3.35 (-12.99%)
Release date Oct 23, 2024
EPS estimate $3.85
EPS actual $3.35
EPS Surprise -12.99%
Revenue estimate 2.036B
Revenue actual 2.03B
Revenue Surprise -0.307%
Q2 2024 Beat
$3.75 (1.90%)
Release date Jul 24, 2024
EPS estimate $3.68
EPS actual $3.75
EPS Surprise 1.90%
Revenue estimate 2.137B
Revenue actual 2.12B
Revenue Surprise -0.790%

Last 4 Quarters for ICON plc

Below you can see how ICLR performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Jul 24, 2024
Fiscal end date Jun 30, 2024
Price on release $331.77
EPS estimate $3.68
EPS actual $3.75
EPS surprise 1.90%
Date Price
Jul 18, 2024 $327.80
Jul 19, 2024 $329.70
Jul 22, 2024 $339.93
Jul 23, 2024 $332.23
Jul 24, 2024 $331.77
Jul 25, 2024 $313.10
Jul 26, 2024 $323.46
Jul 29, 2024 $329.33
Jul 30, 2024 $330.51
4 days before 1.21%
4 days after -0.380%
On release day -5.63%
Change in period 0.83%
Q3 2024 Missed
Release date Oct 23, 2024
Fiscal end date Sep 30, 2024
Price on release $280.76
EPS estimate $3.85
EPS actual $3.35
EPS surprise -12.99%
Date Price
Oct 17, 2024 $295.24
Oct 18, 2024 $297.72
Oct 21, 2024 $288.64
Oct 22, 2024 $283.49
Oct 23, 2024 $280.76
Oct 24, 2024 $221.73
Oct 25, 2024 $220.47
Oct 28, 2024 $230.50
Oct 29, 2024 $232.40
4 days before -4.90%
4 days after -17.22%
On release day -21.03%
Change in period -21.28%
Q4 2024 Beat
Release date Feb 19, 2025
Fiscal end date Dec 31, 2024
Price on release $191.32
EPS estimate $3.41
EPS actual $3.43
EPS surprise 0.587%
Date Price
Feb 12, 2025 $186.53
Feb 13, 2025 $182.64
Feb 14, 2025 $186.21
Feb 18, 2025 $188.65
Feb 19, 2025 $191.32
Feb 20, 2025 $201.84
Feb 21, 2025 $201.39
Feb 24, 2025 $199.15
Feb 25, 2025 $197.50
4 days before 2.57%
4 days after 3.23%
On release day 5.50%
Change in period 5.88%
Q1 2025 Beat
Release date Apr 30, 2025
Fiscal end date Mar 31, 2025
Price on release $151.44
EPS estimate $3.08
EPS actual $3.19
EPS surprise 3.57%
Date Price
Apr 24, 2025 $145.92
Apr 25, 2025 $144.96
Apr 28, 2025 $145.00
Apr 29, 2025 $149.31
Apr 30, 2025 $151.44
May 01, 2025 $145.21
May 02, 2025 $142.96
May 05, 2025 $143.02
May 06, 2025 $135.10
4 days before 3.78%
4 days after -10.79%
On release day -4.11%
Change in period -7.42%

ICON plc Earnings Call Transcript Summary of Q1 2025

Here's a summary of the key points from the ICON plc Q1 2025 earnings call that investors should note:

Market Overview:

  • Cautious Optimism: ICON's management expressed cautious optimism due to mixed indicators in the biotech and large pharma sectors, highlighting a dynamic market environment with elevated cancellations and delays in clinical trials.
  • Mixed Demand: Large pharma demand remains inconsistent, influenced by regulatory issues and budget constraints, while mid-sized pharma shows more potential.
  • Increased Opportunities in Biotech: There is a notable increase in opportunities in the biotech sector, although cancellations and funding uncertainties persist.

Financial Performance:

  • Revenue: Q1 revenue was $2 billion, a decrease of 4.3% year-on-year (3.2% on a constant currency basis).
  • Bookings Performance: The book-to-bill ratio was 1.01, indicating some challenges with project bookings due to elevated cancellations, particularly in the biotech sector.
  • Adjusted EBITDA Margin: The adjusted EBITDA margin was 19.5%, slightly better than expectations, showcasing effective cost management.

Cancellations & Guidance:

  • Elevated Cancellations: The company saw elevated cancellation rates, affecting revenue forecasts. Cancellations stemmed from project prioritization and clinical decisions.
  • Updated Guidance: ICON lowered its full-year revenue guidance by $400 million, with $350 million attributed to canceled COVID-related studies.

Operational & Strategic Focus:

  • Cost Management: ICON is focusing on aligning resources and enhancing efficiencies through operational best practices and automation.
  • Investment in AI Tools: The company released two AI-enabled tools to streamline trial processes, reflecting ongoing investments in technology to improve service delivery.
  • Share Repurchase Strategy: ICON repurchased $250 million in shares during Q1 and plans to continue buying back shares as part of its capital deployment strategy while considering M&A opportunities.

Customer Relationships:

  • Stable Trends with Major Customers: The company is seeing some downtick with its largest customers, but remains confident in its strategic partnerships and the ability to secure new wins.
  • Market Dynamics in China: ICON expects growth opportunities from the expanding clinical trial capabilities in China, bolstered by its established presence in the region.

Conclusion:

ICON management remains proactive in navigating current market challenges, focusing on cost efficiency, strategic investments, and enhancing operational effectiveness. The ongoing investor focus should be on how these strategies will position ICON for sustained growth despite the backdrop of uncertainty in the biotech and pharma markets.

ICON plc Earnings History

Earnings Calendar

FAQ

When is the earnings report for ICLR?
ICON plc (ICLR) has scheduled its earnings report for Jul 23, 2025 after the markets close.

What is the ICLR price-to-earnings (P/E) ratio?
ICLR P/E ratio as of May 12, 2025 (TTM) is 14.45.

What is the ICLR EPS forecast?
The forecasted EPS (Earnings Per Share) for ICON plc (ICLR) for the first fiscal quarter 2025 is $3.21.

What are ICON plc's retained earnings?
On its balance sheet, ICON plc reported retained earnings of $2.00 billion for the latest quarter ending Mar 31, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT ICON PLC
ICON plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, incl...
GOLDEN STAR
Ticker Change Signal Date
MEDP
$300.81
4.30% May 08
BAX
$30.72
3.78% May 07
HBM
$7.41
12.42% May 05
P
PENG
$17.23
9.75% May 05
E
EXE
$105.88
4.76% May 02

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE